Jpmorgan Chase & CO Scynexis Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Scynexis Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 77 shares of SCYX stock, worth $52. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77
Previous 40,199
99.81%
Holding current value
$52
Previous $46,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SCYX
# of Institutions
45Shares Held
12.2MCall Options Held
0Put Options Held
2K-
Federated Hermes, Inc. Pittsburgh, PA2.9MShares$1.97 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$1.52 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.66MShares$1.13 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.23MShares$835,6580.26% of portfolio
-
Amh Equity LTD627KShares$426,3850.97% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $22.2M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...